ClinicalTrials.gg
RecruitingNCT06983080TRADITIONUpdated Dec 8, 2025

Efficacy of Trazodone to Treat Insomnia in Older Adults (TRADITION Study)

A Phase 2 interventional study of Trazodone 25 mg in Insomnia Chronic, Older People and Drug Therapy, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 1 site in Canada. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders — 4 open to participants now, 4 under way, none of them phase 3. Trazodone · Sleep Initiation and Maintenance Disorders.

Planned enrollment
9th of 12
40 · median 146
Started
2025
the only one that year
Phase 2
Only one
of the 12
Registered
10th of 12
by date
Lead sponsor
1 of 12
Centre hospitalier de l'Université de Montréal (CHUM)

Among the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders, this one is the 9th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 2, and was the 10th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

4 of the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About trazodone

Trazodone: first FDA approval 1981 (DESYREL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

This study aims to evaluate how effective trazodone is in treating insomnia in adults aged 65 years and older. The main question it aims to answer is :

- Is trazodone more effective than a placebo in reducing the severity of insomnia symptoms in older adults?

Participants will :

  • Take 25 to 50 mg of trazodone or a matching placebo before bed for 28 days. After a 2-week break, they will then take the other medication for another 28 days.
  • Visit the clinic three times for checkup and test
  • Complete a sleep diary and wear an actimeter during the night.
03

Conditions studied

  • Insomnia Chronic
  • Older People
  • Drug Therapy

Keywords

  • insomia
  • Trazodone
  • Older adults
  • randomized controlled trial
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 65 or older in an outpatient setting
  • Insomnia according to the criteria of the ICSD-3R

Exclusion criteria

Exclusion Criteria:

  • to trazodone ()
  • Presence of a ventricular cardiac arrhythmia (e.g., torsades de pointes)
  • Recent myocardial infarction (\< 6 months)
  • Substances that may alter sleep (hypnotics or any other medication intended to induce sleep, such as mirtazapine or quetiapine, , melatonin, psychostimulant drugs)
  • Active, unstable psychiatric disorder
  • Initiation or titration of an antidepressant within the past 6 months
  • Cognitive-behavioral therapy ongoing or planned during the study period
  • Major neurocognitive disorder (NCD) moderate or severe, or other cognitive disorders that may prevent the participant from being able to participate in the study, according to the judgment of the evaluating physician
  • Parkinson's disease
  • Priapism
  • Known angle-closure glaucoma
  • Symptomatic restless leg syndrome > 3 times per week
  • > 500 ms
  • Parasomnias, dyssomnias other than insomnia
  • Severe sleep apnea with AHI > 30 without CPAP treatment
  • Use of a monoamine oxidase inhibitor
  • Use of a strong CYP 3A4 inducer or inhibitor
  • Hospitalized individuals
  • Seizure within the past 6 months
  • History of orthostatic hypotension
  • History of delirium within the last 6 months
  • Consumption of > 14 alcoholic drinks per day or use of alcohol to induce sleep.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Crossover Trazodone then Placebo arm

    Participants will receive 25 to 50 mg of trazodone once daily at bedtime for 28 days. After a 14-day washout period, participants will receive a placebo for another 28 days.

    Drug: Trazodone 25 mg

  • Experimental
    Crossover Placebo then Trazodone arm

    Participants will receive a placebo once daily at bedtime for 28 days. After a 14-day washout period, participants will receive 25 to 50 mg of trazodone for another 28 days.

    Drug: Trazodone 25 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Insomnia severity index

    The ISI is a self-assessment questionnaire that evaluates the nature, severity, and impact of insomnia. The typical recall period is the past month. The dimensions assessed are: the severity of falling asleep, maintaining sleep, and waking up too early in the morning; sleep dissatisfaction; the interference of sleep difficulties with daytime functioning; the visibility of sleep problems to others; and the distress caused by sleep difficulties. A 5-point Likert scale is used to evaluate each item. The total score is interpreted as follows: no insomnia 0-7; subclinical insomnia 8-14; moderate insomnia 15-21; and severe insomnia 22-28. It is increasingly used as a measure of treatment response in clinical research. Data confirm its reliability and the validity of the measurements obtained in the older adult population.

    Time frame: At baseline or at day 1, at day 36 and at day 77.

Secondary outcomes

  1. Insomnia daytime symptoms and Impacts Questionnaire

    The IDSIQ is a questionnaire covering 14 different items that specifically measures the impact of insomnia on various aspects of daytime functioning. The questions are grouped into three areas, each representing the main daytime symptoms and impacts of insomnia on drowsiness (four items), alertness/cognition (six items), and mood (four items). Each item is rated on an 11-point numerical scale (from 0 to 10), with lower scores indicating better daytime functioning. It has been found to be sensitive to changes in patients experiencing daytime effects. It is quick to administer, easy to complete, and has reliable reproducibility (test-retest). It can be used in clinical trials to assess changes and the effectiveness of a treatment on daytime functioning and for the recording of new drugs for insomnia. Regulatory authorities now require that the effectiveness of clinical trials for medical products against insomnia be measured not only by treating physicians but also by the p

    Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment

  2. Subjective Sleep onset latency

    Subjective time duration, in minutes, between the time the participant attempts to fall asleep (e.g., lights off, lying in bed) and the time they perceive they have fallen asleep.

    Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment

  3. Subjective wake after sleep onset

    The perceived total duration, in minutes, of all periods of wakefulness occurring after initial sleep onset and before final awakening

    Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment

  4. Subjective Total sleep time

    The perceived total duration, in minutes, of actual sleep obtained during the night, excluding periods of wakefulness.

    Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment

  5. Subjective sleep efficiency

    The perceived percentage of time spent asleep while in bed, calculated as the ratio of subjective total sleep time (sTST) to time in bed (TIB), multiplied by 100

    Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment

  6. Objective sleep onset latency

    The estimated duration, in minutes, between the time the participant attempts to fall asleep (e.g., lights out or bedtime) and the onset of the first sustained period of sleep, as detected by actigraphy

    Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment

  7. Objective Wake After Sleep Onset

    The estimated total duration, in minutes, of wakefulness occurring after the initial sleep onset and before final awakening, as detected by actigraphy

    Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment

  8. Objective Total Sleep Time

    The estimated total duration, in minutes, of actual sleep obtained during the sleep period, as detected by actigraphy, excluding all periods of wakefulness

    Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment

  9. Objective Sleep Efficiency

    The estimated percentage of time spent asleep while in bed, calculated as the ratio of objective total sleep time (oTST) to objective time in bed (oTIB), multiplied by 100 as measured by actigraphy.

    Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment

  10. Adverse events

    Incidence of at least one adverse event. Incidence of severe adverse events. Proportion of participants who discontinued due to adverse events.

    Time frame: At Day 36 and day 77

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no need since it is a single center study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 20 months after the start.

Of 63 phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 20 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
May 21, 2025
StartActual
Nov 10, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2027
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06983080
Responsible party
Sponsor
First posted
May 21, 2025
Start date
Nov 10, 2025
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Dec 8, 2025

Study contacts

Patrick Nguyen, B. Pharm, M.Sc.
Contact
patrick.nguyen.chum@ssss.gouv.qc.ca
514-890-8000 ext. 36163

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion